Gene Panel Predicts Damage in Donated Kidneys
By LabMedica International staff writers Posted on 04 Aug 2016 |

Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Kidney transplantation is a life-extending procedure and a panel of genes has been identified that can help predict whether a transplanted kidney will later develop fibrosis, an injury which can cause the organ to fail.
Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.
A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.
Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).
The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.
Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.
Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.
A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.
Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).
The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.
Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.
Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Latest Pathology News
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
Channels
Clinical Chemistry
view channel
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more